and the other two were diagnosed at autopsy. In addition to the three reports, we have reviewed the published experience on toxoplasmosis in North American and other Toxoplasma infection following bone marrow transplantation (BMT) is infrequently reported. We report BMT centers. three cases of disseminated toxoplasmosis in BMT recipients documented during an 8-year period at our institution: one after an unrelated marrow transplant Case No. 1 in a toxoplasma-seronegative patient, the second complicating syngeneic marrow transplantation, and the A 29-year-old woman with acute lymphoblastic anemia in third remission received a HLA-identical bone marrow third following allogeneic, related BMT. The disease is extremely rare in seronegative patients and has not been transplant from an unrelated donor. The woman was toxoplasma-seronegative and the donor's serostatus was not previously reported in syngeneic recipients. Toxoplasmosis was diagnosed at autopsy in two of the three known. Preparative therapy included cyclophosphamide and total body irradiation. While receiving high-dose cyclocases. We also present a review of all reported cases of toxoplasmosis in marrow recipients from North Amerphosphamide, the patient developed hypotension, prolonged QT interval on electrocardiogram and congestive ican and other BMT centers. Heightened awareness of the occurrence of toxoplasmosis in marrow recipients heart failure. With aggressive supportive care, these symptoms resolved and she then received her marrow transplant. and early diagnostic/therapeutic measures are needed for a better outcome.
tiple blood and stool cultures (bacterial, viral) failed to Discussion reveal any specific organism. Clostridium difficile toxin assay was negative. Radioimmunoassay of stool for rotaToxoplasmosis is an uncommon infection occurring usually between 60 and 150 days after marrow transplantation.
1,2 virus was positive. Colonoscopy with biopsy failed to reveal any specific etiology of her persistent diarrhea. On In an analysis of 2000 marrow transplants at the Fred Hutchinson Cancer Center in Seattle, 3 the incidence of disday +19, there was engraftment of donor marrow. Bone marrow examination documented complete remission of seminated toxoplasmosis was 0.31 per 100 allogeneic BMT recipients and 1 per 100 autopsies. Of the 12 reported cases, acute leukemia with disappearance of the Philadelphia chromosome. Fever and diarrhea, however, persisted. An two were diagnosed ante-mortem, 10 were diagnosed at autopsy, and all were fatal. indium scan on day +46 post-BMT revealed increased lung uptake suggestive of a diffuse inflammatory process. She
Excluding the three cases in the present report, a total of 52 cases of disseminated toxoplasmosis following BMT underwent a bronchoscopy with alveolar lavage. Within 4 h, respiratory failure with diffuse bilateral pulmonary infilhave been reported in the English language literature.
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Twenty-five cases have been reported from US BMT centrates developed. Despite aggressive supportive care, her cardiorespiratory status gradually deteriorated and she ters and 27 from BMT centers (Tables 1 and 2) 25 Two of these cases occurred due to reactivation of previously documented and An 18-year-old woman received allogeneic BMT from her HLA-identical sister for chronic myelogenous leukemia treated ocular toxoplasmosis. To the best of our knowledge, the present case No. 2 is the first documented report of (CML). Both donor and recipient were seropositive for toxoplasmosis and cytomegalovirus (CMV); IgM antidisseminated toxoplasmosis following syngeneic BMT. Probably, impaired cellular and humoral immunity consebodies for toxoplasma were absent in donor and recipient. No risk factor for acquisition of toxoplasma infection was quent to the preparative regimen predisposed the syngeneic marrow recipient to reactivation of latent protozoal infecidentified. She received busulfan and cytoxan for cytoreduction, and cyclosporine + methotrexate for post-graft tion. It is well recognized that autologous marrow recipients, though without GVHD, frequently develop reactiimmunosuppression. She also received norfloxacin and fluconazole for selective gut decontamination during granuvation of latent viral infections like varicella-zoster. As most cases of toxoplasmosis have been seen in BMT recipilocytopenia. On day +21 post-BMT, she developed nausea, vomiting, diarrhea, palmar erythema and skin rash clinients who are seropositive prior to BMT, it is widely believed that toxoplasmosis occurs by reactivation of latent cally consistent with acute GVHD. With a presumptive diagnosis of GVHD, she was treated with methylprednisoinfection. A few cases (including present case No. 1) have occurred in BMT recipients with negative toxoplasma antilone (2 mg/kg/day) with prompt resolution of the skin rash and gastrointestinal symptoms. Methylprednisolone was body titers. In these, the infection may have occurred due to transmission of infection via marrow or blood products. tapered and she remained symptom free until day +60 when she developed nausea, vomiting, crampy abdominal pain,
In the present case No. 1, rapid onset of signs/symptoms consistent with a serious disseminated infectious process diarrhea and skin rash involving 50% of the body surface. She was admitted to the hospital with an acute exacerbation occurring soon after transplantation suggests the possibility of transplant-related toxoplasma transmission. Jurges et al 22 of GVHD. Histology of the biopsies of skin and upper and lower gastrointestinal tracts were consistent with acute reported disseminated toxoplasmosis in a seronegative patient who received marrow from a seropositive donor. GVHD. Therapy with methylprednisolone (2 mg/kg/day) and cyclosporine (3 mg/kg/day) intravenously was initiated.
The donor T cells were depleted in vivo by a monoclonal T cell antibody (Campath 1G). The authors speculated that Although the skin rash resolved completely, the diarrhea worsened and she developed high-grade fevers with blood impaired cell-mediated immunity as a result of ablation of specific committed memory donor T cells by the monocultures remaining sterile. Examination of a colonic biopsy on day +83 showed intracellular inclusions in cells of the clonal antibody could have been responsible for the dissemination of transmitted toxoplasma infection. Alternaterminal ileum suggestive of cytomegalovirus (CMV) infection. Though cultures for CMV were negative, treattively, it has been suggested that the antibody titer prior to BMT in immunosuppressed individuals may falsely be ment with ganciclovir and immunoglobulin (IVIG) was initiated. On day +90 she developed acute respiratory disnegative.
9,10
The usual onset of symptoms is between the 2nd and 4th tress, hypoxemia and bilateral interstitial infiltrates on chest X-ray. Thoracoscopic lung biopsy revealed interstitial month following BMT in most reported cases. In a few instances, the onset occurs as early as 9 days or as late as pneumonitis due to toxoplasma. Therapy with trimethoprim-sulfamethoxazole (TMP-SMX) and clindamycin was 1 year after BMT. Only four of the 55 reported cases survived the infection. Toxoplasmosis presents most combegun. Despite aggressive supportive care, she died on day +94 post-BMT from progressive respiratory insufficiency.
monly with encephalitis; occasionally congestive heart failure due to myocarditis or respiratory failure due to bilateral Permission for autopsy was denied. Br = brain; H = heart; L = lungs; Li = liver; NR = not reported; GVHD = graft-versus-host disease; PCR = polymerase chain reaction; Thy = thyroid; S = spleen; LN = lymph nodes; EM = electron microscopy. Br = brain; H = heart; L = lungs; Li = liver; NR = not reported; GVHD = graft-versus-host disease; PCR = polymerase chain reaction; BAL = bronchoalveolar lavage.
pneumonitis, retino choroiditis or fever of unknown origin ents pre-and-post BMT. They observed that of the 29 seronegative BMT recipients of marrow from seropositive and non-specific symptoms may be the presenting features. Toxoplasma meningitis without focal lesions has been donors, three experienced a transient sero-conversion post-BMT without developing overt clinical manifestations of reported in one instance. 21 Although pre-transplant toxoplasma serology can identtoxoplasmosis. None of the seronegative recipients developed overt clinical toxoplasmosis. On the other hand, ify patients at high risk for toxoplasma reactivation, serial serological tests post-BMT have been unpredictable, makof the 54 seropositive patients, four patients developed cerebral toxoplasmosis and had a rise in antibody titer posting early diagnosis extremely difficult. 18 In one case, the diagnosis was made after examination of the cerebrospinal fluid. 10 Because of difficulties unexplained encephalitis, myocarditis or pneumonitis. As effective antitoxoplasma therapy is available, early in confirming the diagnosis, some cases were diagnosed on the basis of clinical and radiological findings alone, 14, 20 diagnostic/therapeutic intervention should result in a better outcome in this otherwise uniformly fatal infection. while others were diagnosed on the basis of improvement in the clinical picture following empiric therapy against toxoplasmosis. In one case, the diagnosis was made by electron microscopy. 16 standard regimen in the treatment of toxoplasmosis. For
